Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nationâs leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. Source
No articles found.
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision med...
MyoKardia is a clinical-stage biopharmaceutical...
The Healthereum Patient Behavior Management platform is a full cycle communication...
The Healthereum Patient Behavior Management pla...
MTBC is a healthcare information technology company that provides a fully integrat...
MTBC is a healthcare information technology com...
Alkermes plc is a fully integrated, global biopharmaceutical company developing in...
Alkermes plc is a fully integrated, global biop...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Join the National Investor Network and get the latest information with your interests in mind.